Johnson & Johnson's (JNJ) planned acquisition of Ollin Biosciences for up to $3.3 billion is a potential growth driver beyond 2030, UBS Securities said in a Monday note.
Ollin Biosciences' lead asset OLN324 has features that position it to deliver better anatomical benefits than the FDA-approved faricimab therapy, the brokerage said.
OLN324 is being developed for eye conditions like wet age-related macular degeneration and diabetic macular edema, and has demonstrated "very promising" phase 1b data in both indications against faricimab, UBS noted.
Ollin Biosciences is advancing the product candidate into phase 3 studies for said indications, with potential data readout in late 2028 or early 2029 and potential filings and approval in late 2029 or 2030, the firm said.
Should OLN324 demonstrate comparable vision outcomes with faricimab, plus improved anatomical benefits, it could present a revenue opportunity of more than $5 billion for Johnson & Johnson, UBS added.
UBS has a buy rating on Johnson & Johnson, with a $320 price target.
Price: 280.12, Change: -2.43, Percent Change: -0.86
Comments